Omzet 2024 * | 81,33 mln. 75,3 mln. | Omzet 2025 * | 78,22 mln. 72,43 mln. | Marktkapitalisatie | 16,87 mln. 15,62 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -13 mln. -12,04 mln. | Nettowinst (verlies) 2025 * | 4 mln. 3,7 mln. | EV/omzet 2024 * | 0,21 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,22 x |
K/w-verhouding 2024 * |
-1,22
x | K/w-verhouding 2025 * |
3,94
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,43% |
Recentste transcriptie over Aytu Bioscience Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joshua Disbrow
CEO | Chief Executive Officer | 49 | 16-04-15 |
Jarrett Disbrow
FOU | Founder | 49 | 16-04-15 |
Mark Oki
DFI | Director of Finance/CFO | 55 | 17-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Vivian Liu
BRD | Director/Board Member | 62 | 01-07-22 |
Jarrett Disbrow
FOU | Founder | 49 | 16-04-15 |
Joshua Disbrow
CEO | Chief Executive Officer | 49 | 16-04-15 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+45,82% | 765 mld. | |
+40,95% | 632 mld. | |
-6,16% | 354 mld. | |
+19,86% | 331 mld. | |
+9,32% | 299 mld. | |
+18,45% | 248 mld. | |
+11,88% | 216 mld. | |
-0,78% | 219 mld. | |
+5,90% | 164 mld. |